Evidence-focused registry notes
Trial Tracker
A careful, registry-first view of active, completed, and planned human studies involving ibogaine and noribogaine, current through September 30, 2026.
How to use this page
Start with the record, not the headline.
Trial registries preserve details that short announcements often leave out: eligibility, intended enrollment, outcomes, comparator groups, and whether a study is recruiting or only planned.
This tracker is a living index rather than a treatment directory. It follows registry entries, protocol-facing documents, and result disclosures where they are public. The ClinicalTrials.gov study registry is a central primary record for many U.S.-registered human studies, while its status fields should still be read as sponsor- or investigator-maintained information.
For broader context on substance-use research, the evidence and safety overview helps place trial activity beside uncertainty, screening, and the difference between experimental research and established care. Basic terms also matter: ibogaine is a psychoactive alkaloid, and the general ibogaine reference entry notes its origin and longstanding scientific interest without resolving questions about clinical use.
Interpretation note: “Active,” “recruiting,” “completed,” and “planned” describe study administration—not a finding that an intervention works or is appropriate for an individual.
Searches can be widened through ibogaine location context, but a location listing is separate from a registered trial and should never substitute for verifying a study identifier, sponsor, protocol, or oversight information.
What each record needs
The fields that make a trial legible.
A useful record identifies an NCT or equivalent registry number, sponsor, phase where assigned, indication, intervention, primary endpoints, planned enrollment, status, dates, and source record. It should also say whether a design is randomized, blinded, open-label, controlled, or observational.
- Differentiate ibogaine from noribogaine; related compounds cannot be treated as interchangeable interventions.
- Separate a registry record from a peer-reviewed publication, preprint, sponsor announcement, or absent results.
- Keep outcome wording intact, because a primary endpoint is not the same as an eventual conclusion.
For a plain-language map of mechanisms under discussion, how ibogaine may work can help distinguish pharmacology questions from claims about outcomes. The tracker does not infer results from a mechanism or from a sponsor’s stated rationale.
Status language
A record can be current and still incomplete.
Timelines change. Recruitment may pause. Results may be delayed, selectively reported, or unavailable. The most responsible entry makes those limits visible.
For each study, this page is designed to capture the trial identifier, sponsor, phase, indication, intervention, primary endpoints, enrollment status, design, timeline, and the strongest publicly accessible source. When a record identifies opioid-use disorder, alcohol-use disorder, traumatic brain injury, or another indication, that diagnosis describes the study question rather than proof of therapeutic effect.
Status convention
- Identifier
- Use the registry number or a clearly named official study record; do not create an identifier when one is not public.
- Design
- State randomization, masking, comparator, dosing framework, and follow-up only as the primary source describes them.
- Results
- Mark peer-reviewed, preprint, press release, registry-posted, or not yet available rather than blending those categories.
- Safety
- Flag publicly reported serious safety incidents and link the primary disclosure where it exists.
The FDA’s description of the drug-development process is a useful reminder that phase labels and clinical investigations are components of an evidence pathway, not automatic authorization. Related regulatory context belongs alongside study status, particularly where a compound’s legal status or investigational pathway is changing.
For readers comparing research activity with commercial treatment messaging, independent treatment review context is best read separately from a trial entry. A clinic-oriented claim, testimonial, or marketing announcement is not a substitute for a protocol, registry record, or published result.
Evidence boundaries
Safety reporting belongs in the same frame.
Ibogaine study updates are not neutral if they omit cardiac and medical risk context. The design, screening, monitoring, and adverse-event reporting are part of what readers need to assess.
Ibogaine has been associated with potentially serious cardiac rhythm concerns. That is why registry details such as exclusion criteria, ECG-related procedures, concomitant medications, inpatient observation, and adverse-event reporting deserve attention alongside efficacy endpoints. Publicly reported incidents should be described precisely, without extrapolating beyond the source.
Readers looking at brain injury questions can compare experimental study language with brain and aging research context, while keeping the distinction between hypothesis, trial design, and demonstrated clinical outcome intact. The National Institute of Neurological Disorders and Stroke overview of traumatic brain injury similarly provides established context for the condition, not evidence that an investigational compound treats it.
What is strongest
“A registry entry is a starting point for verification—not a verdict on safety, effectiveness, or availability.”
Tracker standard
What to flag
Publicly reported deaths, arrhythmias, other serious adverse events, protocol pauses, recruitment changes, and withdrawals should be visible where a reliable primary source documents them. Absence of a public report does not demonstrate absence of risk.
Those considering care outside research settings should keep Mexico treatment context distinct from registered clinical trials and should review the site’s safety and risk considerations before treating any claim as personal guidance.
Questions readers ask
A careful way to follow updates.
Trial tracking is most useful when it preserves uncertainty rather than filling gaps with inference.
Does a registered trial mean ibogaine is established treatment?
No. A registry listing documents a study plan or status; it does not establish effectiveness, routine availability, or regulatory approval. Trial design, safety monitoring, results, and peer review all matter.
Why can a trial record and a publication differ?
A registry may be updated at different times than a paper is written or released. Records can change, recruitment can pause, and a study may report only some planned outcomes. The tracker distinguishes registry information from published findings.
What safety context belongs beside ibogaine trial updates?
Ibogaine has been associated with potentially serious cardiac rhythm risk and other medical concerns. A study listing should not be interpreted as individualized medical guidance or a sign that unsupervised use is safe.
Where can the site’s method and scope be checked?
The resource’s approach and independence statement explains the broader evidence-first standard, while the regulatory timeline adds context for legal and investigational developments that can affect how a study record is interpreted.
Keep context close
Research activity is not personal medical advice.
Use the safety material to read trial announcements with the medical uncertainty and risk context they require.